PL381823A1 - Leczenie czynności napadowej z zastosowaniem inhibitorów ICE - Google Patents

Leczenie czynności napadowej z zastosowaniem inhibitorów ICE

Info

Publication number
PL381823A1
PL381823A1 PL381823A PL38182305A PL381823A1 PL 381823 A1 PL381823 A1 PL 381823A1 PL 381823 A PL381823 A PL 381823A PL 38182305 A PL38182305 A PL 38182305A PL 381823 A1 PL381823 A1 PL 381823A1
Authority
PL
Poland
Prior art keywords
ice inhibitors
treating seizures
seizures
treating
inhibitors
Prior art date
Application number
PL381823A
Other languages
English (en)
Other versions
PL217743B1 (pl
Inventor
Annamaria Vezzani
John C.R. Randle
Original Assignee
Vertex Pharmaceuticals Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated
Publication of PL381823A1 publication Critical patent/PL381823A1/pl
Publication of PL217743B1 publication Critical patent/PL217743B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL381823A 2004-05-15 2005-05-16 Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw PL217743B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57131404P 2004-05-15 2004-05-15

Publications (2)

Publication Number Publication Date
PL381823A1 true PL381823A1 (pl) 2007-07-23
PL217743B1 PL217743B1 (pl) 2014-08-29

Family

ID=34969808

Family Applications (1)

Application Number Title Priority Date Filing Date
PL381823A PL217743B1 (pl) 2004-05-15 2005-05-16 Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw

Country Status (12)

Country Link
US (2) US20060128696A1 (pl)
EP (1) EP1750689A1 (pl)
JP (2) JP4848367B2 (pl)
CN (2) CN1980648A (pl)
AU (1) AU2005247409B2 (pl)
CA (1) CA2566362C (pl)
IL (1) IL179248A0 (pl)
MX (1) MXPA06013256A (pl)
NZ (1) NZ588448A (pl)
PL (1) PL217743B1 (pl)
WO (1) WO2005115362A1 (pl)
ZA (1) ZA200610133B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295054A1 (en) * 2004-05-27 2011-03-16 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
AU2007254990A1 (en) * 2006-05-31 2007-12-13 Vertex Pharmaceuticals Incorporated Oral controlled release formulations of an interleukin-1 beta converting enzyme inihibitor
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
RU2537361C1 (ru) * 2013-07-18 2015-01-10 Общество С Ограниченной Ответственностью "Синтегал" Оптические изомеры (+) и (-)-бензгидрилмочевин и (+) и (-)-1-[(3-хлорфенил)-фенил-метил]мочевины, фармацевтическая композиция на их основе и способ их получения
EP3426230B1 (en) * 2016-03-10 2024-08-07 Orphelia Pharma Solid dosage forms of vigabatrin
MX2022013549A (es) 2020-05-01 2023-01-16 Medstar Health Inc Metodos para tratar la covid-19.
WO2024097731A2 (en) * 2022-11-02 2024-05-10 Medstar Health, Inc. Methods for treating covid-19

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) * 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US5985863A (en) * 1996-09-12 1999-11-16 Vertex Pharmaceuticals, Inc. Compositions and methods for decreasing IGIF and IFN-γ production by administering an ICE inhibitor
US5416013A (en) * 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
US6995141B1 (en) * 1990-04-04 2006-02-07 Vertex Pharmaceuticals Incorporated Interleukin 1β protease and interleukin 1β protease inhibitors
EP0600880B1 (en) * 1991-08-30 2004-01-07 Vertex Pharmaceuticals Incorporated Interleukin 1- beta protease and interleukin 1-beta protease inhibitors
US5985838A (en) * 1993-04-29 1999-11-16 Vertex Pharmaceuticals, Inc. Peptide analogs as irreversible interleukin-1β protease inhibitors
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US5843905A (en) * 1993-06-04 1998-12-01 Vertex Pharmaceuticals, Incorporated Peptidic phosphinyloxymethyl ketones as interleukin-1β-converting enzyme inhibitors
EP0628550B1 (en) * 1993-06-08 1998-02-25 Sanofi Pyridazines as interleukin-1beta converting enzyme inhibitors
CN1504462A (zh) * 1994-03-31 2004-06-16 ������˹ҩƷ��˾ 作为白细胞介素抑制剂的嘧啶基衍生物
US5552400A (en) * 1994-06-08 1996-09-03 Sterling Winthrop Inc. Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) * 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US5856116A (en) * 1994-06-17 1999-01-05 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1 beta converting enzyme
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
US5834514A (en) * 1995-05-30 1998-11-10 Vertex Pharmaceuticals, Incorporated Halomethyl amides as IL-1β protease inhibitors
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6096728A (en) * 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6610683B2 (en) 1996-09-12 2003-08-26 Idun Pharmaceuticals, Inc. Treatment of infectious disease using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US6531467B2 (en) 1996-09-12 2003-03-11 Idun Pharmaceuticals, Inc. Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
DE69734718T2 (de) 1996-09-12 2006-08-24 Idun Pharmaceuticals, Inc., San Diego Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
IL129026A0 (en) 1996-10-11 2000-02-17 Warner Lambert Co Sulfonamide interleukin-1beta converting enzyme inhibitors
AU738341B2 (en) 1996-10-11 2001-09-13 Abbott Gmbh & Co. Kg Asparate ester inhibitors of interleukin-1beta converting enzyme
US6083981A (en) 1996-10-11 2000-07-04 Warner-Lambert Company Sulfonamide substituted aspartic acid interleukin-1β converting enzyme inhibitors
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
AU7624798A (en) * 1996-12-06 1998-06-29 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1 beta converting enzyme
ATE290545T1 (de) * 1996-12-06 2005-03-15 Vertex Pharma Inhibitoren des interleukin-1beta konvertierenden enzyms
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
DE69811404T2 (de) 1998-01-20 2003-12-04 Abbott Gmbh & Co. Kg N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2-(4-flurophenyl)1,6-dihydro-1-pyrimidinyl)acetoxyl)-l-asparaginsäure aldehyde als in vivo inhibitor des interleukin-1beta konvertierenden enzyms
DE69925581T2 (de) * 1998-03-09 2006-04-27 Vertex Pharmaceuticals Inc., Cambridge 1,2-diazepanderivate als inhibitoren des interleukin-1beta umwandelnden enzyms
AU755273B2 (en) 1998-03-16 2002-12-05 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
ID27002A (id) 1998-03-19 2001-02-22 Vertex Pharma Penghambat-penghambat kaspase
KR20010052307A (ko) 1998-05-05 2001-06-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인터루킨-1β 전환 효소의 숙신아미드 저해제
AU4318799A (en) * 1998-06-02 1999-12-20 Vertex Pharmaceuticals Incorporated Caspase-9 deficient animals and the use thereof
CA2367340A1 (en) 1999-03-16 2000-09-21 Cytovia, Inc. Substituted 2-aminobenzamide caspase inhibitors and the use thereof
ATE363465T1 (de) 1999-04-09 2007-06-15 Cytovia Inc Caspase inhibitoren und ihre verwendung
DK1163208T3 (da) * 1999-08-06 2004-08-16 Vertex Pharma Caspaseinhibitorer og anvendelser deraf
CA2383002A1 (en) 1999-08-27 2001-03-08 Cytovia, Inc. Substituted .alpha.-hydroxy acid caspase inhibitors and the use thereof
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
CA2389569A1 (en) * 1999-11-16 2001-05-25 Vertex Pharmaceuticals Incorporated Crystallizable compositions comprising a caspase-7
AR026748A1 (es) * 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
HRP20020782A2 (en) * 2000-03-29 2004-12-31 Vertex Pharma Carbamate caspase inhibitors and uses thereof
IL152393A (en) * 2000-04-24 2008-03-20 Vertex Pharma Process for making aspartic acid acetal derivatives
AU2001257253B2 (en) * 2000-05-04 2006-03-02 Vertex Pharmaceuticals Incorporated Asymmetric synthesis of piperazic acid and derivatives thereof
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US7053057B2 (en) * 2000-05-23 2006-05-30 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
IL152845A0 (en) * 2000-06-07 2003-06-24 Vertex Pharma Fused heterocyclic compounds and pharmaceutical compositions containing the same
CA2315468A1 (en) 2000-08-10 2002-02-10 Thermax International Corp. Multi grouting system
PE20020500A1 (es) * 2000-09-13 2002-06-25 Vertex Pharma Derivados de piperidina, tetrahidroquinolina, tetrahidroisoquinolina como inhibidores de caspasas
US7205327B2 (en) * 2000-11-21 2007-04-17 Vertex Pharmaceuticals Incorporated Imidazole and benzimidazole caspase inhibitors and uses thereof
MXPA03009647A (es) * 2001-04-19 2004-01-29 Vertex Pharma Heterociclildicarbamidas como inhibidores de caspasa.
AU2002305552A1 (en) 2001-05-10 2002-11-18 Abbott Gmbh And Co.Kg Arylsulfonamide ethers, and methods of use thereof
WO2002094263A2 (en) * 2001-05-23 2002-11-28 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
EP1436248A2 (en) * 2001-10-09 2004-07-14 Vertex Pharmaceuticals Incorporated Process for synthesizing aspartic and glutamic acid derivatives and diazoketone intermediates thereof
US20030232788A1 (en) 2002-02-08 2003-12-18 Idun Pharmaceuticals, Inc. (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases
US7410956B2 (en) * 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
US20050171023A1 (en) 2002-04-05 2005-08-04 Cai Sui X. Caspase inhibitors for the treatment of diseases and conditions caused by exposure to radionuclides, biological agents, or chemical agents
US7960398B2 (en) * 2002-04-19 2011-06-14 Vertex Pharmaceuticals Incorporated Regulation of TNF-alpha
US7138395B2 (en) 2002-06-10 2006-11-21 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
US7001899B2 (en) 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
US7041696B2 (en) 2002-06-17 2006-05-09 The Procter & Gamble Company Interleukin-1β converting enzyme inhibitors
BR0312232A (pt) 2002-06-28 2005-05-10 Vertex Pharma Inibidores de caspases e seus usos
WO2004058718A1 (en) 2002-12-20 2004-07-15 Vertex Pharmaceuticals Incorporated 4-oxo-3-(1-oxo-1h-isoquinolin-2-ylacetylamino)-pentanoic acid ester and amide derivatives and their use as caspase inhibitors
PE20050159A1 (es) * 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
NZ544472A (en) 2003-07-03 2009-04-30 Myriad Genetics Inc Compounds and therapeutical use thereof
CA2545733A1 (en) * 2003-11-10 2005-05-26 Vertex Pharmaceuticals Incorporated Methods for monitoring il-18
AU2004294343A1 (en) * 2003-12-01 2005-06-16 Vertex Pharmaceuticals Incorporated Treating infectious diseases using ICE inhibitors
EP1718639A2 (en) * 2004-02-27 2006-11-08 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
KR101135765B1 (ko) * 2004-03-12 2012-04-23 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
EP2295054A1 (en) * 2004-05-27 2011-03-16 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
CN101098855B (zh) * 2004-11-24 2012-06-06 沃泰克斯药物股份有限公司 3-[2-(3-酰氨基-2-氧代-2h-吡啶-1-基)-乙酰氨基]-4-氧代-戊酸衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途
CA2616337A1 (en) * 2005-07-28 2007-02-08 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs

Also Published As

Publication number Publication date
US20060128696A1 (en) 2006-06-15
CN1980648A (zh) 2007-06-13
CA2566362A1 (en) 2005-12-08
JP2011213741A (ja) 2011-10-27
MXPA06013256A (es) 2007-02-08
AU2005247409B2 (en) 2011-11-10
JP2007538013A (ja) 2007-12-27
NZ588448A (en) 2012-01-12
CA2566362C (en) 2013-09-10
IL179248A0 (en) 2008-04-13
JP4848367B2 (ja) 2011-12-28
AU2005247409A1 (en) 2005-12-08
PL217743B1 (pl) 2014-08-29
EP1750689A1 (en) 2007-02-14
CN102362867A (zh) 2012-02-29
WO2005115362A1 (en) 2005-12-08
US20150190404A1 (en) 2015-07-09
ZA200610133B (en) 2008-05-28

Similar Documents

Publication Publication Date Title
IL179398A0 (en) Dpp-ib inhibitors
ZA200703079B (en) DNA-PK Inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200802867B (en) Fap inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
IL190442A0 (en) Phenyl-acetamide nnrt inhibitors
IL183129A0 (en) Lipase inhibitors
SI1725528T1 (sl) Sulfonilpiroli kot HDAC inhibitorji
IL177037A (en) Kimase inhibitors
GB0400290D0 (en) dUTPase inhibitors
WO2005072713A3 (en) Cholinesterase inhibitors for treating inflammation
IL179305A0 (en) Dpp-iv inhibitors
IL190081A0 (en) Nnrt inhibitors
EP1940397A4 (en) METHOD FOR TREATING HYPERTONIA
SG10201403828PA (en) Lipase inhibitors
GB0421355D0 (en) Inhibitors
PL381823A1 (pl) Leczenie czynności napadowej z zastosowaniem inhibitorów ICE
EP1799244A4 (en) INHIBITORS OF FURINE
EP1890690A4 (en) MAO-B INHIBITORS FOR TREATING OBESITY
EP1816194A4 (en) CANCER-SPECIFIC PROLIFERATION INHIBITORS
EP1789055A4 (en) INHIBITORS OF THIAZOLOPYRIDINE KINASE
GB0515327D0 (en) Comt inhibitors
GB0421356D0 (en) Inhibitors
SG115849A1 (en) Corrosion inhibition method
GB0318913D0 (en) Apoptosis inhibitors